SGI-1776 free base

SGI-1776 free base

Catalog Number:
L002369084APE
Mfr. No.:
APE-A4192
Price:
$260
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Please contact us at for specific academic pricing.

          Background

          SGI-1776 free base, N-((1-methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine, is a potent ATP-competitive inhibitor of the serine/threonine family of Pim kinase, an enzyme regulating cell survival. Through extensive biomedical characterization, SGI-1776 exhibits specificity to the three isoforms of the Pim family, including Pim-1, Pim-2, and Pim-3. According to preliminary results from studies treating prostate cancer cells, SGI-1776 dose-dependently reduces phosphorylation of known Pim kinase substrates involved in cell cycle progression and apotosis (p21Cip1/WAF1 and Bad), compromises overall cell viability by inducing G1 cell cycle arrest and triggering apoptosis, and reduces cell viability in a multidrug resistance 1 (MDR1) protein based taxane-refractory prostate cancer cell line.

      • Properties
        • Alternative Name
          SGI1776,SGI 1776; N-[(1-methylpiperidin-4-yl)methyl]-3-[3-(trifluoromethoxy)phenyl]imidazo[1,2-b]pyridazin-6-amine
          CAS Number
          1025065-69-3
          Molecular Formula
          C20H22F3N5O
          Molecular Weight
          405.42
          Appearance
          A solid
          Purity
          99.28%
          Solubility
          ≥40.5 mg/mL in DMSO; insoluble in H2O; ≥101 mg/mL in EtOH
          Storage
          Store at -20°C

          * For Research Use Only

      • Reference
        • 1. Whillock AL, Mambetsariev N, et al. "TRAF3 regulates the oncogenic proteins Pim2 and c-Myc to restrain survival in normal and malignant B cells." Sci Rep. 2019 Sep 9;9(1):12884. PMID:31501481
          2. Nurbek Mambetsariev. "Mechanisms of TRAF3 mediated regulation of B cell survival." University of Iowa.2018.
          3. Kris Cameron Wood,Peter Saville Winter. "Compositions and Methods for Treating Cancer with JAK2 Activity." US Patent App. 15/027,216, 2016.
          4. Winter PS, et al. "RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis." Sci Signal. 2014 Dec 23. PMID:25538080

    We Also Recommend

    SMI-4a

    $228

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.